Incyte Corporation (INCY)

In the past six months, Incyte's stock has experienced significant movement due to several key events. As of May 8, 2026, the stock has seen a 63.69% total shareholder return over the past year. On May 1, 2026, Incyte announced FDA approval of Jakafi XR™ for myelofibrosis, polycythemia vera, and graft-versus-host disease. On April 28, 2026, Incyte reported strong first-quarter 2026 financial results, with total net sales reaching $1.27 billion and adjusted EPS of $1.81, reaffirming its full-year 2026 guidance. On April 28, 2026, Suketu (Suky) Upadhyay was appointed as Chief Financial Officer, effective May 4, 2026. On March 25, 2026, Incyte announced executive leadership appointments. On March 28, 2026, Incyte announced positive 54-week late-breaking data for Povorcitinib in Hidradenitis Suppurativa. In January 2026, positive tafasitamab data was shared. The stock was up approximately 43% over the past year as of January 2, 2026. In May 2024, Incyte acquired Escient Pharmaceuticals for $750 million, adding two oral drug candidates for inflammatory diseases. In May 2024, Incyte expanded its presence in Delaware with the acquisition of two office buildings in Wilmington.

The demand for Incyte's products and services is generally not subject to significant seasonality, as its products are primarily pharmaceuticals for chronic medical conditions. Demand for treatments for such conditions tends to be stable throughout the year, rather than fluctuating with seasons. While stock performance may exhibit some seasonality, this does not directly reflect the demand for the company's pharmaceutical products.

Incyte Corp. is a global biopharmaceutical company focused on discovering, developing, and commercializing proprietary therapeutics, operating within the Biotechnology industry. Its core business addresses unmet medical needs through medicines and a pipeline concentrated in Oncology and Inflammation & Autoimmunity. Key products include Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease; Opzelura (ruxolitinib cream) for atopic dermatitis and vitiligo; Pemazyre (pemigatinib) for biliary tract cancer; Monjuvi/Minjuvi (tafasitamab) for lymphoma; Iclusig (ponatinib) for leukemia; Tabrecta (capmatinib) for non-small cell lung cancer; Olumiant (baricitinib) for rheumatoid arthritis, atopic dermatitis, and alopecia areata; Zynyz (retifanlimab-dlwr) for Merkel cell carcinoma; and Niktimvo (axatilimab-csfr) for chronic graft-versus-host disease.

Incyte is a multinational pharmaceutical company with operations in North America, Europe, and Asia. Its headquarters are in Wilmington, Delaware, U.S., with a European headquarters in Morges, Switzerland. The company's medicines and clinical programs are referenced in the United States, Europe, and Japan, with specific operations in the U.S., Canada, Japan, Germany, Italy, Spain, Portugal, and the United Kingdom.

In the past year, Incyte's brand reputation appears to be strong and positive, driven by successful product development, regulatory approvals, and robust financial performance. News sentiment for Incyte is "Very Bullish," with 100% bullish news and 0% bearish news reported. This positive perception is due to strong demand and sales growth, FDA approval of Jakafi XR, positive clinical trial data for pipeline candidates, strategic acquisitions like Escient Pharmaceuticals, and reaffirmation of strong financial guidance for 2026. There are no readily available reports of specific negative events that have significantly impacted Incyte's brand reputation in the past year.

Incyte's ownership is primarily held by institutional investors, who collectively hold a substantial portion of the company's stock. Major institutional owners include Baker Bros. Advisors LP, The Vanguard Group, Inc., Dodge & Cox, BlackRock Institutional Trust Company, N.A., State Street Investment Management (US), AQR Capital Management, LLC, Renaissance Technologies LLC, Geode Capital Management, LLC, and LSV Asset Management. Approximately 57.47% of the company's stock is owned by Institutional Investors, 15.19% by Insiders, and 27.34% by Public Companies and Individual Investors.